FDA approves gene therapy for MPS IIIA
The one-time intravenous treatment uses adeno-associated virus serotype 9 to deliver a functional copy of the SGSH gene.
-
By
-
Kathryn Wighton
-
September 18, 2026
-
Clinical Scorecard: FDA approves gene therapy for MPS IIIA
At a Glance
| Category | Detail |
|---|
| Condition | Mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A) |
| Key Mechanisms | Rebisufligene etisparvovec introduces a functional copy of the SGSH gene using modified adeno-associated virus serotype 9. |
| Target Population | Pediatric patients with mucopolysaccharidosis type IIIA. |
| Care Setting | Health care setting where infusion reactions can be managed. |
Key Highlights
- First FDA-approved treatment for MPS IIIA.
- Single intravenous infusion of rebisufligene etisparvovec.
- Cognitive function remained stable or improved post-treatment.
- Adverse reactions include increased liver enzymes, nausea, and thrombotic microangiopathy.
- Corticosteroids are administered before and after infusion.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of MPS IIIA should be confirmed through genetic testing.
Management
- Rebisufligene etisparvovec is indicated for treatment.
Monitoring & Follow-up
- Monitor cognitive outcomes and adverse reactions post-infusion.
Risks
- Long-term risk of tumor development due to genomic integration.
Patient & Prescribing Data
Pediatric patients diagnosed with MPS IIIA.
Treatment involves a single intravenous infusion with pre- and post-infusion corticosteroids.
Clinical Best Practices
- Administer in a setting equipped to manage infusion reactions.
- Conduct regular monitoring of liver enzymes and cognitive function.
Related Resources & Content
